Nasdaq · CIK 0001346830
TVRD Tvardi Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Feb 2, 2026. Close $1.03 on Oct 9, 2026, 0% from the 52-week low and -98% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
TVRDOct 9, 2026 · close 1.03
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Tvardi Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 3Weak | Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. sell | $776 163 shares | -2% | - | |
| 13Weak | Christopher Posner PRESIDENT AND CEO sell | $2,769 583 shares | -4% | - | |
| 5Weak | Christopher Posner PRESIDENT AND CEO sell | $1,756 372 shares | -3% | - | |
| 5Weak | Christopher Posner PRESIDENT AND CEO sell | $1,064 3,668 shares | -2% | - |
Transactions
The last 49 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 29, 2026 | Avi Daniel Conn Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Feb 2, 2026 |
| Jan 29, 2026 | John Saewook Kauh M.D. Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Feb 2, 2026 |
| Jan 29, 2026 | Stephen Paul O'Brien Principal Accounting Officer | AGrant or award Employee Stock Option (right to buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Feb 2, 2026 |
| Jan 29, 2026 | Imran Nizamudin Alibhai Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Feb 2, 2026 |
| Dec 16, 2025 | Imran Nizamudin Alibhai Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +47,500 | $0.00 | $0 | 47,500 | Dec 18, 2025 |
| Dec 16, 2025 | Avi Daniel Conn Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Dec 18, 2025 |
| Dec 16, 2025 | John Saewook Kauh M.D. Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Dec 18, 2025 |
| Dec 16, 2025 | Stephen Paul O'Brien Principal Accounting Officer | AGrant or award Employee Stock Option (right to buy)derivative | +4,000 | $0.00 | $0 | 4,000 | Dec 18, 2025 |
| Jul 7, 2025 | Samuel David Tweardy owner | JOther Common Stockindirect: By Trust | -315,658 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Jul 7, 2025 | Samuel David Tweardy owner | JOther Common Stockindirect: By Trust | -315,658 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Apr 15, 2025 | Wallace L Hall Jr director | AGrant or award Common Stockindirect: Firepit Partners, LP | +44,712 | - | - | 44,712 | May 2, 2025 |
| Apr 15, 2025 | Shaheen Wirk director | AGrant or award Common Stockindirect: Palkon Holdings, LLC | +176,030 | - | - | 176,030 | May 2, 2025 |
| Apr 15, 2025 | Wallace L Hall Jr director | AGrant or award Common Stockindirect: BioMatrix Partners Ltd. | +202,044 | - | - | 202,044 | May 2, 2025 |
| Apr 15, 2025 | Shaheen Wirk director | AGrant or award Common Stockindirect: Palkon TT Holdings, LLC | +263,164 | - | - | 263,164 | May 2, 2025 |
| Apr 17, 2025 | Jeffrey Leroy Larson SVP, Research & Development | AGrant or award Employee Stock Option (right to buy)derivative | +10,820 | $0.00 | $0 | 10,820 | Apr 21, 2025 |
| Apr 17, 2025 | Stephen Paul O'Brien Principal Accounting Officer | AGrant or award Employee Stock Option (right to buy)derivative | +7,213 | $0.00 | $0 | 7,213 | Apr 21, 2025 |
| Apr 17, 2025 | Sujal Shah director | AGrant or award Stock Option (right to buy)derivative | +12,000 | $0.00 | $0 | 12,000 | Apr 21, 2025 |
| Apr 17, 2025 | Susan Shiff Ph.D. director | AGrant or award Stock Option (right to buy)derivative | +12,000 | $0.00 | $0 | 12,000 | Apr 21, 2025 |
| Apr 17, 2025 | Cynthia Smith director | AGrant or award Stock Option (right to buy)derivative | +12,000 | $0.00 | $0 | 12,000 | Apr 21, 2025 |
| Apr 17, 2025 | Michael S Wyzga director | AGrant or award Stock Option (right to buy)derivative | +12,000 | $0.00 | $0 | 12,000 | Apr 21, 2025 |
| Apr 17, 2025 | Shaheen Wirk director | AGrant or award Stock Option (right to buy)derivative | +12,000 | $0.00 | $0 | 12,000 | Apr 21, 2025 |
| Apr 17, 2025 | Avi Daniel Conn Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +43,547 | $0.00 | $0 | 43,547 | Apr 21, 2025 |
| Apr 17, 2025 | Imran Nizamudin Alibhai Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +182,320 | $0.00 | $0 | 182,320 | Apr 21, 2025 |
| Apr 17, 2025 | Wallace L Hall Jr director | AGrant or award Stock Option (right to buy)derivative | +12,000 | $0.00 | $0 | 12,000 | Apr 21, 2025 |
| Apr 17, 2025 | Yixin Chen VP, Chem, Mfg and Ctrls | AGrant or award Employee Stock Option (right to buy)derivative | +7,213 | $0.00 | $0 | 7,213 | Apr 21, 2025 |
| Apr 17, 2025 | John Saewook Kauh M.D. Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +36,210 | $0.00 | $0 | 36,210 | Apr 21, 2025 |
| Apr 15, 2025 | Shaheen Wirk director | AGrant or award Common Stock | +4,191 | - | - | 4,191 | Apr 17, 2025 |
| Apr 15, 2025 | Sujal Shah director | AGrant or award Stock Option (right to buy)derivative | +10,394 | - | - | 10,394 | Apr 17, 2025 |
| Apr 15, 2025 | Stephen Paul O'Brien Principal Accounting Officer | AGrant or award Employee Stock Option (right to buy)derivative | +11,399 | - | - | 11,399 | Apr 17, 2025 |
| Apr 15, 2025 | Michael S Wyzga director | AGrant or award Stock Option (right to buy)derivative | +18,441 | - | - | 18,441 | Apr 17, 2025 |
| Apr 15, 2025 | Jeffrey Leroy Larson SVP, Research & Development | AGrant or award Employee Stock Option (right to buy)derivative | +16,764 | - | - | 16,764 | Apr 17, 2025 |
| Apr 15, 2025 | John Saewook Kauh M.D. Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +74,049 | - | - | 74,049 | Apr 17, 2025 |
| Apr 15, 2025 | Wallace L Hall Jr director | JOther Common Stockindirect: Firepit Partners, LP | +44,712 | - | - | 44,712 | Apr 17, 2025 |
| Apr 15, 2025 | Avi Daniel Conn Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +89,053 | - | - | 89,053 | Apr 17, 2025 |
| Apr 15, 2025 | Yixin Chen VP, Chem, Mfg and Ctrls | AGrant or award Employee Stock Option (right to buy)derivative | +14,752 | - | - | 14,752 | Apr 17, 2025 |
| Apr 15, 2025 | Imran Nizamudin Alibhai Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +207,881 | - | - | 207,881 | Apr 17, 2025 |
| Apr 15, 2025 | Wallace L Hall Jr director | JOther Common Stockindirect: BioMatrix Partners Ltd. | +202,044 | - | - | 202,044 | Apr 17, 2025 |
| Apr 15, 2025 | Shaheen Wirk director | JOther Common Stockindirect: Palkon Holdings, LLC | +176,030 | - | - | 176,030 | Apr 17, 2025 |
| Apr 15, 2025 | Sujal Shah director | AGrant or award Stock Option (right to buy)derivative | +8,047 | - | - | 8,047 | Apr 17, 2025 |
| Apr 15, 2025 | Stephen Paul O'Brien Principal Accounting Officer | AGrant or award Employee Stock Option (right to buy)derivative | +3,352 | - | - | 3,352 | Apr 17, 2025 |
| Apr 15, 2025 | Jeffrey Leroy Larson SVP, Research & Development | AGrant or award Employee Stock Option (right to buy)derivative | +5,364 | - | - | 5,364 | Apr 17, 2025 |
| Apr 15, 2025 | Imran Nizamudin Alibhai Chief Executive Officer | AGrant or award Employee Stock Optyion (right to buy)derivative | +2,011 | - | - | 2,011 | Apr 17, 2025 |
| Apr 15, 2025 | Imran Nizamudin Alibhai Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +160,940 | - | - | 160,940 | Apr 17, 2025 |
| Apr 15, 2025 | Shaheen Wirk director | JOther Common Stockindirect: Palkon TT Holdings, LLC | +263,164 | - | - | 263,164 | Apr 17, 2025 |
| Apr 15, 2025 | Shaheen Wirk director | AGrant or award Stock Option (right to buy)derivative | +2,011 | - | - | 2,011 | Apr 17, 2025 |
| Feb 28, 2025 | Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. | SOpen-market sale Common Stock10b5-1 | -163 | $4.76 | $776 | 7,190 | Mar 4, 2025 |
| Feb 28, 2025 | Christopher Posner PRESIDENT AND CEO | SOpen-market sale Common Stock10b5-1 | -583 | $4.75 | $2,769 | 13,109 | Mar 4, 2025 |
| Feb 4, 2025 | Christopher Posner PRESIDENT AND CEO | SOpen-market sale Common Stock10b5-1 | -372 | $4.72 | $1,756 | 13,692 | Feb 6, 2025 |
| Nov 4, 2024 | Christopher Posner PRESIDENT AND CEO | SOpen-market sale Common Stock10b5-1 | -3,668 | $0.29 | $1,064 | 168,768 | Nov 6, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Imran Nizamudin AlibhaiChief Executive Officer
- Yixin ChenVP, Chem, Mfg and Ctrls
- Avi Daniel ConnChief Financial Officer
- Wallace L Hall Jrdirector
- John Saewook Kauh M.D.Chief Medical Officer
- Jeffrey Leroy LarsonSVP, Research & Development
- Stephen Paul O'BrienPrincipal Accounting Officer
- Christopher PosnerPRESIDENT AND CEO
- Sujal Shahdirector
- Susan Shiff Ph.D.director
- Cynthia Smithdirector
- Scott TerrillionSEC'Y; CHIEF COMPLIANCE & G.C.
- Samuel David Tweardyowner
- Michael S Wyzgadirector
- Shaheen Wirkdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.